{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:30:12Z","timestamp":1793939412725,"version":"4.8.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neurol.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T03:30:52Z","timestamp":1726284652000},"page":"957-962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["What's new in NMOSD and MOGAD?"],"prefix":"10.1016","volume":"180","author":[{"given":"R.","family":"Marignier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2024.08.004_bib0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.004_bib0150","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"issue":"11\u201312","key":"10.1016\/j.neurol.2024.08.004_bib0155","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2024.08.004_bib0160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.004_bib0165","doi-asserted-by":"crossref","first-page":"e200183","DOI":"10.1212\/NXI.0000000000200183","article-title":"Timing of MOG-IgG testing is key to 2023 MOGAD diagnostic criteria","volume":"11","author":"Forcadela","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.004_bib0170","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1177\/13524585231198754","article-title":"Validation of the international MOGAD panel proposed criteria","volume":"29","author":"Kim","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2024.08.004_bib0175","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jamaneurol.2023.3956","article-title":"Ongoing challenges in the diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"80","author":"Lipps","year":"2023","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2024.08.004_bib0180","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1007\/s00415-024-12438-6","article-title":"Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings","volume":"271","author":"Rechtman","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.08.004_bib0185","doi-asserted-by":"crossref","first-page":"105150","DOI":"10.1016\/j.msard.2023.105150","article-title":"Utility of the 2023 international MOGAD panel proposed criteria in clinical practice: an institutional cohort","volume":"81","author":"Alaboudi","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2024.08.004_bib0190","doi-asserted-by":"crossref","first-page":"105544","DOI":"10.1016\/j.msard.2024.105544","article-title":"Exclusion of alternative diagnoses: a component of the 2023 MOGAD criteria that belongs at the forefront, not in the background","volume":"85","author":"Budhram","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.neurol.2024.08.004_bib0195","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/WCO.0000000000001265","article-title":"Clinical characteristics of patients with myelin oligodendrocyte glycoprotein antibodies","volume":"37","author":"Maillart","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurol.2024.08.004_bib0200","doi-asserted-by":"crossref","first-page":"e1376","DOI":"10.1212\/WNL.0000000000207478","article-title":"Timing and predictors of T2-lesion resolution in patients with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"101","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurol.2024.08.004_bib0205","first-page":"426","article-title":"Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course","volume":"95","author":"Abdel-Mannan","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.08.004_bib0210","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.08.004_bib0215","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1093\/brain\/awad122","article-title":"Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids","volume":"146","author":"Matsumoto","year":"2023","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.neurol.2024.08.004_bib0220","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2024.08.004_bib0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ana.26931","article-title":"Diagnostic utility of MOG antibody testing in cerebrospinal fluid","volume":"96","author":"Redenbaugh","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.004_bib0230","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2024-333554","article-title":"Clinical, prognostic and pathophysiological implications of MOG-IgG detection in the CSF: the importance of intrathecal MOG-IgG synthesis","author":"Greco","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.neurol.2024.08.004_bib0235","doi-asserted-by":"crossref","first-page":"e209199","DOI":"10.1212\/WNL.0000000000209199","article-title":"MOG antibodies restricted to CSF in children with inflammatory CNS disorders","volume":"102","author":"Oliv\u00e9-Cirera","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2024.08.004_bib0240","doi-asserted-by":"crossref","first-page":"e200188","DOI":"10.1212\/NXI.0000000000200188","article-title":"Serum biomarker profiles discriminate AQP4 seropositive and double seronegative neuromyelitis optica spectrum disorder","volume":"11","author":"Carta","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.neurol.2024.08.004_bib0245","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/jnnp-2022-330707","article-title":"Anti-Argonaute antibodies as a potential biomarker in NMOSD","volume":"94","author":"Carta","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.neurol.2024.08.004_bib0250","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2023.2523","article-title":"Immunoglobulin A antibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with central nervous system demyelination","volume":"80","author":"Ayroza Galv\u00e3o Ribeiro Gomes","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.08.004_bib0255","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jnnp-2022-330360","article-title":"Time to steroids impacts visual outcome of optic neuritis in MOGAD","volume":"94","author":"Rode","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.neurol.2024.08.004_bib0260","doi-asserted-by":"crossref","first-page":"e200065","DOI":"10.1212\/NXI.0000000000200065","article-title":"Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD","volume":"10","author":"Nosadini","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.neurol.2024.08.004_bib0265","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.26731","article-title":"Do early relapses predict the risk of long-term relapsing disease in an adult and paediatric cohort with MOGAD?","volume":"94","author":"Chen","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.08.004_bib0270","doi-asserted-by":"crossref","first-page":"951423","DOI":"10.3389\/fneur.2022.951423","article-title":"Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report","volume":"13","author":"Chatterton","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.08.004_bib0275","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10072-023-06971-x","article-title":"Eculizumab for a catastrophic relapse in NMOSD: case report","volume":"45","author":"Gorriz","year":"2024","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.neurol.2024.08.004_bib0280","doi-asserted-by":"crossref","first-page":"e200150","DOI":"10.1212\/NXI.0000000000200150","article-title":"Dramatic response to anti-IL-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease","volume":"10","author":"McLendon","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T17:35:47Z","timestamp":1730396147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724005861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0035378724005861"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.08.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What's new in NMOSD and MOGAD?","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}